Share ownership InnoCan Pharma Corporation

INNO

CA45783P5085

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 02:40:42 2026-02-18 pm EST			5-day change	1st Jan Change
8.080 ^CAD	-1.22%		+27.04%	+20.60%

Feb. 09	InnoCan Pharma Says Latest LPT-CBD Trial Involving Dogs Published in Peer-Reviewed Journal	MT
Jan. 27	Innocan Pharma Expects Listing on the NYSE American Stock Exchange with Concurrent Offering	MT

Share class: InnoCan Pharma Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	286,938,271	222,340,565 ( 77.49 %)	0	77.49 %

Major shareholders: InnoCan Pharma Corporation

Name	Equities	%	Valuation
Solsken Ltd. 17.01 %	765,039	17.01 %	5 M $
Ron Abraham Mayron 2.306 %	103,746	2.306 %	725 185 $
Iris Bincovich 1.841 %	82,826	1.841 %	578 954 $
Eyal Flom 0.9339 %	42,014	0.9339 %	293 678 $
Roni Kamhi 0.228 %	10,257	0.228 %	71 696 $
Ralph Bossino 0.1299 %	5,846	0.1299 %	40 864 $
Nelson Halpern 0.1187 %	5,339	0.1187 %	37 320 $
Joshua Lintern 0.0845 %	3,800	0.0845 %	26 562 $
Peter Bloch 0.0136 %	611	0.0136 %	4 271 $

Breakdown by shareholder type

Other	17.01%
Individuals	5.66%
Unknown	77.33%

Based on 1000 largest holdings

Geographical origin of shareholders

Canada	17.01%
Individuals	5.66%

Based on 1000 largest holdings

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company